CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

 

 

April 30, 2025

 

WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that CD8 Technology Services LLC (“CD8”) has signed a letter of intent for a facility designed to support Tevogen Bio’s cell therapy manufacturing facility.

 

Tevogen Founder and CEO, Ryan Saadi, MD, MPH commented, “In-house manufacturing is critical to our operational efficiency, and with 74% insider ownership, we place the highest value on business discipline.”

 

 

 

Contacts

 

Tevogen Communications
T: 1 877 TEVOGEN, Ext 701
communications@Tevogen.com